Search Results

You are looking at 21 - 30 of 265 items for :

  • "expectancy" x
  • Refine by Access: All x
Clear All
Full access

Counterpoint: The Case for Immediate Active Treatment

Stacy Loeb and William J. Catalona

Active monitoring strategies recently have received attention as possible treatment options for men with low-risk prostate cancer who have a life expectancy of more than 10 years. However, no current criteria sufficiently predict outcomes for individuals with clinically localized disease and an otherwise long life expectancy who undergo either immediate or delayed treatment, or no treatment. This article describes the available evidence regarding treatment outcomes in men with low-risk prostate cancer and presents the case for immediate active treatment.

Full access

HSR19-102: Direct and Indirect Economic Burden of Cervical Cancer (CxCa) in the United States in 2015: A Mixed-Methods Analysis

Chizoba Nwankwo, Shelby L. Corman, Ruchit Shah, and Youngmin Kwon

data on the age-stratified number of CxCa deaths per year (1935–2015) and life expectancy data from the Social Security Administration were then used to calcluate the number of women who would be alive in 2015 if they had not died from CxCa and the lost

Full access

What Is the Appropriate Approach to Treating Women With Incurable Cervical Cancer?

Lois Ramondetta

strictures, fistulas, vaginal agglutination/sexual dysfunction, and chronic pain. Unresectable recurrent disease may be associated with all of these symptoms, along with disturbing malodorous discharge and bleeding, and is associated with a life expectancy

Full access

Undertreatment of High-Risk Localized Prostate Cancer in the California Latino Population

Daphne Y. Lichtensztajn, John T. Leppert, James D. Brooks, Sumit A. Shah, Weiva Sieh, Benjamin I. Chung, Scarlett L. Gomez, and Iona Cheng

progression and death in light of the patient's current life expectancy, functional status, and quality of life. Any gains in future life expectancy resulting from treatment must be balanced against potential losses in quality of life. Based on this decision

Full access

Early and Midtreatment Mortality in Palliative Radiotherapy: Emphasizing Patient Selection in High-Quality End-of-Life Care

Matthew S. Ning, Prajnan Das, David I. Rosenthal, Bouthaina S. Dabaja, Zhongxing Liao, Joe Y. Chang, Daniel R. Gomez, Ann H. Klopp, G. Brandon Gunn, Pamela K. Allen, Paige L. Nitsch, Rachel B. Natter, Tina M. Briere, Joseph M. Herman, Rebecca Wells, Albert C. Koong, and Mary Frances McAleer

proportion of patients dying shortly after or during RT stems from difficulties in predicting life expectancies accurately for terminally ill patients. 17 , 18 Provider tendencies to overestimate survival lead to challenges with tailoring palliative regimens

Full access

Management of Primary Ovarian Insufficiency Symptoms in Survivors of Childhood and Adolescent Cancer

Emma Gargus, Rebecca Deans, Antoinette Anazodo, and Teresa K. Woodruff

POI is associated with increased mortality. In a Dutch cohort of 12,000 women followed over 17 years, life expectancy of women with POI was 2 years less than that of controls. 53 Similar results have been seen in non-Caucasian populations, including

Full access

PSA Screening for Prostate Cancer: Why Saying No is a High-Value Health Care Choice

Timothy J. Wilt and Philipp Dahm

history curve and the patient benefits from earlier detection. Patient 3 has slowly growing cancer that will not cause symptoms during his or her lifetime. Patient 4 has serious noncancer health risks that decrease life expectancy and prevent benefit from

Full access

Prostate Cancer

Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute

To properly identify and treat patients with prostate cancer, physicians must have an in-depth understanding of the natural history and diagnostic, staging, and treatment options. Prostate cancer is a complex disease, with many controversial aspects of management and a dearth of sound data to support recommendations. Several variables must be considered in tailoring prostate cancer therapy to each individual patient. These guidelines provide a framework on which to base treatment decisions. Important changes to the guidelines since last publication include the introduction of Principles of Life Expectancy Estimation table and changes in recommendations for both hormone and chemotherapy.

For the most recent version of the guidelines, please visit NCCN.org

Full access

Breast Cancer Screening and Diagnosis Clinical Practice Guidelines

The University of Alabama at Birmingham Comprehensive Cancer Center

The lifetime risk of a woman developing breast cancer has increased over the past 5 years in the United States: of every 7 women, 1 is at risk based on a life expectancy of 85 years. An estimated 214,640 new cases (212,920 women and 1,720 men) of breast cancer and 41,430 deaths (40,970 women and 460 men) from this disease will occur in the United States in 2006. However, mortality from breast cancer has decreased slightly, attributed partly to mammographic screening. Early detection and accurate diagnosis made in a cost-effective manner are critical to a continued reduction in mortality. These practice guidelines are designed to facilitate clinical decision making.

For the most recent version of the guidelines, please visit NCCN.org

Full access

New NCCN Guidelines: Cancer Management in People Living With HIV

Gita Suneja

Since the emergence of HIV in the United States in the 1980s, cancer has been a part of the story. The good news is that antiretroviral therapy has improved survival for those living with HIV infection, with life expectancy now approaching that of uninfected people. Consequently, this patient population is living long enough to develop different types of cancer. At the 23rd NCCN Annual Conference, Gita Suneja, MD, MSHP, presented the debut of the new NCCN Guidelines for Cancer in People Living With HIV, discussing the intersection between cancer and HIV infection, the cancers most likely to develop in this group of patients, and the importance of oncologists working in conjunction with HIV specialists to render the most appropriate and individualized care.